Arbutus Biopharma Corporation

Nicholas Michael Snead

Amy C H Lee

Emily P Thi

James Heyes

Mark Wood

Richard James Holland

Alan Martin

Ian MacLachlan

Adam Judge

Ammen P Dhillon

Xin Ye

Jennifer L Cross

The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).

Targeted compositions

The present invention provides compositions comprising therapeutic nucleic acids such as siRNA that target Hepatitis B virus (HBV) gene expression, lipid particles comprising one or more (e.g., a combination) of the therapeutic nucleic acids, and methods of delivering and/or administering the lipid particles (e.g., for treating HBV infection and/or HDV infection in humans).

Compositions and methods for silencing hepatitis B virus gene expression

Growing community of inventors

San Francisco, CA, United States of America

Nicholas Michael Snead